World's leading clinical conference on bone, joint and muscle health
Programme
Sunday April 13 th - CEST Timezone
08:00 - 09:00
Non-Sponsored Symposia
08:00
MR3
Perioperative Bone Optimization in Arthroplasty Candidates with Osteoporosis
Chairperson: Rafael Jimenez-Umbarila
Chairperson: Rafael Jimenez-Umbarila
08:00
MR3
Updated Joint Positions on Perioperative Bone Optimization in Arthroplasty Candidates 2024
08:00
MR3
Current Practices, Needs, and Challenges in Periprosthetic Bone Mineral Density Assessment: Towards Standardization
08:00
MR3
Current Practices and Educational Needs in Perioperative Bone Optimization for Arthroplasty Candidates: Survey Results
08:00
MR4
The intimate relationship between adipose and bone tissue
Chairperson: Yannis Dionyssiotis
Chairperson: Yannis Dionyssiotis
08:00
MR4
Adipose and bone tissue. A close relationship
08:00
MR4
Metabolic syndrome. A paradigm of the intimate relationship between adipose and bone tissue
08:00
MR4
Metabolic syndrome and osteoporosis
08:00
MR4
Metabolic syndrome and diet. Do they affect bone mass?
08:00
MR4
Metabolic syndrome and depression
08:00
MR1
Update on the Study to Advance BMD as a Regulatory Endpoint (SABRE): What Might Osteoporosis Trials look like in the Future?
Chairperson: Mary Bouxsein
Chairperson: Mary Bouxsein
08:00
MR1
Challenges of Clinical Trials for New Osteoporosis Medications
08:00
MR1
Evidence Supporting the Use of BMD as a Surrogate Endpoint for Fractures
08:00
MR1
Considerations for designing trials that use BMD as a Primary EndpointKyphoplasty
08:00
MR2
Improving Women’s Bone Health Throughout the Lifespan
Chairpersons: Adriana Orcesi Pedro, Maria Celeste Osório Wender
Chairpersons: Adriana Orcesi Pedro, Maria Celeste Osório Wender
08:00
MR2
Opening and Welcome from FEBRASGO
08:00
MR2
Bone Consequences of Premature Ovarian Insufficiency (POI)
08:00
MR2
The Role of Hormone Therapy in the Management of Postmenopausal
08:00
MR2
Evaluation and management of osteopenia and osteoporosis in breast cancer survivors
08:00
MR7
Developing Clinical Practice Guidelines for Osteoporosis Diagnosis and Management in Middle-Income Countries: Challenges and Opportunities
Chairperson: Geraldine Altamar
Chairperson: Geraldine Altamar
08:00
MR7
Why a clinical practice guideline in a middle-income country like Colombia?
08:00
MR7
Challenges in the development of clinical practice guidelines in a middle-income country
08:00
MR7
Opportunities in the development of clinical practice guidelines
08:00
MR8
European and American Efforts to Educate the Public and Health Care Professionals on the Connection Between Spine and Bone Health
Chairperson: Rita Roy
Chairperson: Rita Roy
08:00
MR8
Osteoporosis and the Spine Overview: Key Statistics and an Overview of the National Spine Health Foundation’s Key Patient and Health Care Professional Initiatives
08:00
MR8
A Spine Surgeon Perspective on the Need for Spine and Bone Health Optimization
08:00
MR8
A European Perspective on Key Spine Surgeon Gaps in the Diagnosis and Treatment of Osteoporotic Patients
08:00
MR10
Navigating the Complex Interplay of Aging, Chronic Kidney Disease, and Osteoporosis: Case-Based Challenges and Treatment Insights
Chairpersons: Nathalie van der Velde, Tahir Masud
Chairpersons: Nathalie van der Velde, Tahir Masud
08:00
MR10
Setting the Stage: Understanding the Intersection of Aging, CKD, and Osteoporosis – Key Concepts and Clinical Approaches
08:00
MR10
Managing Skeletal Fragility in the Context of CKD: Practical Insights
08:00
MR10
Real-World Challenges and Personalized Strategies in Diagnosis and Treatment
08:00 - 09:00
MR5
ESCEO Symposium on PTH1 RA: Use of parathyroid hormone receptor agonists in the management of osteoporosis: State of the art
Chairpersons: Nicholas C. Harvey, Claudia Campusano
Chairpersons: Nicholas C. Harvey, Claudia Campusano
08:00
MR5
Pharmacological mode of action
08:00
MR5
Anti-fracture efficacy of PTH R1A
08:00
MR5
Safety of PTH R1A in the management of osteoporosis
08:00
MR5
Discussion leader
08:00 - 09:00
MR6
SICOT-ESCEO-IOF Symposium: Fragility Fractures - Importance of Interdisciplinary Management
Chairpersons: Veronika Koeppen-Ursic, Marc Hanschen
Chairpersons: Veronika Koeppen-Ursic, Marc Hanschen
08:00
MR6
Fragility Fractures of the Pelvic Ring – Minimal Invasive Treatment Options
08:00
MR6
Decision Making in the Management of Fragility Fractures of the Acetabulum
08:00
MR6
Interdisciplinary Comprehensive Care of Fragility Fractures in Germany
08:00
MR6
15 Years of Experience with Atypical Femoral Fractures
09:00 - 10:00
Poster Viewing Session III
09:00 - 10:00
Meet-The-Expert Session
09:00
MR1
Magnesium, nutrition and musculoskeletal disorders
09:00
MR4
Osteoarthritis: a bone or a joint disorder?
09:00
MR2
GIOP: present and future
09:00
MR3
Artificial intelligence in patient management
09:00 - 10:00
MR5
Sponsored Meet-The-Expert Session
* See details on the Sponsored Satellite Symposia page
* See details on the Sponsored Satellite Symposia page
09:00 - 10:00
MR6
ESCEO-EMAS Joint Symposium: Risks and management of osteoporosis in menopausal women
Chairpersons: Angelica Lindén Hirschberg, Radmila Matijevic
Chairpersons: Angelica Lindén Hirschberg, Radmila Matijevic
09:00
MR6
Association between early menopause and fracture risk
09:00
MR6
Ovarian volume and bone mineral density in postmenopausal women
09:00
MR6
What do current guidelines recommend about MHT and osteoporosis prevention in menopausal women?
10:00 - 12:00
Auditorium A
Scientific Session VII
Chairpersons: Lakshmi Nagendra, Claudia Campusano, Manju Chandran
Chairpersons: Lakshmi Nagendra, Claudia Campusano, Manju Chandran
10:00
Auditorium A
Plenary Lecture
When should we consider moving from medical to surgical management in osteoarthritis of the knee and hip?
When should we consider moving from medical to surgical management in osteoarthritis of the knee and hip?
10:40
Auditorium A
Oral communications selected from abstracts
OC36: A NATIONAL SURVEY OF AUSTRALIAN PRIMARY CARE CLINICIANS’ KNOWLEDGE, BELIEFS, ATTITUDES, PRACTICES, PERCEPTIONS OF RESPONSIBILITY AND BARRIERS AND ENABLERS TO IDENTIFICATION AND MANAGEMENT OF SARCOPENIA
OC36: A NATIONAL SURVEY OF AUSTRALIAN PRIMARY CARE CLINICIANS’ KNOWLEDGE, BELIEFS, ATTITUDES, PRACTICES, PERCEPTIONS OF RESPONSIBILITY AND BARRIERS AND ENABLERS TO IDENTIFICATION AND MANAGEMENT OF SARCOPENIA
10:50
Auditorium A
Oral communications selected from abstracts
OC37: AUTOMATED ABDOMINAL AORTIC CALCIFICATION EXTENT IS ASSOCIATED WITH MUSCLE COMPOSITION, STRENGTH AND SARCOPENIA: THE UK BIOBANK IMAGING STUDY
OC37: AUTOMATED ABDOMINAL AORTIC CALCIFICATION EXTENT IS ASSOCIATED WITH MUSCLE COMPOSITION, STRENGTH AND SARCOPENIA: THE UK BIOBANK IMAGING STUDY
11:00
Auditorium A
Oral communications selected from abstracts
OC38: ROMOSOZUMAB AND DENOSUMAB COMBINATION THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS
OC38: ROMOSOZUMAB AND DENOSUMAB COMBINATION THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS
11:10
Auditorium A
Oral communications selected from abstracts
OC39: FIVE-YEARS OF CALCIUM SUPPLEMENTATION IS NOT ASSOCIATED WITH LONG-TERM RISK OF DEMENTIA IN OLDER WOMEN: POST-HOC ANALYSIS FROM A RANDOMISED CLINICAL TRIAL
OC39: FIVE-YEARS OF CALCIUM SUPPLEMENTATION IS NOT ASSOCIATED WITH LONG-TERM RISK OF DEMENTIA IN OLDER WOMEN: POST-HOC ANALYSIS FROM A RANDOMISED CLINICAL TRIAL
11:20
Auditorium A
Oral communications selected from abstracts
OC40: THE EFFECT OF DENOSUMAB ON FUNCTIONAL RECOVERY IN OLDER PATIENTS UNDERGOING SURGICAL FIXATION FOR INTERTROCHANTERIC FEMORAL FRACTURE: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL
OC40: THE EFFECT OF DENOSUMAB ON FUNCTIONAL RECOVERY IN OLDER PATIENTS UNDERGOING SURGICAL FIXATION FOR INTERTROCHANTERIC FEMORAL FRACTURE: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL
11:30
Auditorium A
Plenary Lecture
Successful fracture healing: do osteoporosis and its treatment matter?
Successful fracture healing: do osteoporosis and its treatment matter?
12:00 - 13:00
Non-Sponsored Symposia
12:00
MR1
HIV, bone quality and quantity, and fracture risk: insights from studies in Zimbabwe and South Africa
Chairpersons: Lisa Micklesfield, Teréza Hough
Chairpersons: Lisa Micklesfield, Teréza Hough
12:00
MR1
HIV and it’s treatments on fracture risk: a scoping review
12:00
MR1
Fractures E3 focussing on vertebral fractures
12:00
MR1
Clinical risk factors associated with fracture risk in middle-aged men and women from Soweto, Johannesburg: findings from the Middle-aged Soweto Cohort (MASC)
12:00
MR1
The influence of HIV on bone quality, quantity and fracture risk in midlife women: findings from a cross-sectional study in Zimbabwe
12:00
MR2
Potential driving mechanisms behind sarcopenia: where are we now?
Chairperson: Evelien Gielen
Chairperson: Evelien Gielen
12:00
MR2
Exploring the role of inflammageing in sarcopenia – a quick overview
12:00
MR2
The gut-muscle axis in sarcopenia: bridging gut microbiota, inflammation and diet
12:00
MR2
Sarcopenia and the Brain: unravelling the Muscle-Brain Axis in the development and treatment of Sarcopenia
12:00
MR2
Conclusion and discussion of the symposium
12:00
MR3
Fibromyalgia. Pain and musculoskeletal manifestations
Chairperson: Panagiotis Athanassiou
Chairperson: Panagiotis Athanassiou
12:00
MR3
Fibromyalgia as a systemic autoimmune disease affecting the bone
12:00
MR3
Fibromyalgia in the context of autoimmune rheumatic diseases
12:00
MR3
Fibromyalgia in the context of autoimmune thyroid disease
12:00
MR3
Fibromyalgia and pain
12:00
MR3
Fibromyalgia, pain and psychological implications
12:00
MR4
Managing the Discontinuation of Denosumab Therapy
Chairperson: David Kendler
Chairperson: David Kendler
12:00
MR4
Denosumab: Long-term Therapy and Discontinuation
12:00
MR4
Managing Denosumab Discontinuation in Patients with Osteoporosis
12:00
MR4
Managing the Discontinuation of Denosumab in Patients on Hormone Ablative Therapy for Non-metastatic Cancer with Osteoporosis
12:00
MR5
The Importance of Osteosarcopenia Today
Chairpersons: Nasser Al-Daghri, Gustavo Duque
Chairpersons: Nasser Al-Daghri, Gustavo Duque
12:00
MR5
Epidemiological facts about osteosarcopenia
12:00
MR5
The molecular pathways of osteosarcopenia
12:00
MR5
How to treat osteosarcopenia
12:00
MR6
Latin American Patients’ perceptions on osteoporosis diagnosis and treatment. The IOF Patient Advisory Group in Latin America
Chairperson: Joan Levin
Chairperson: Joan Levin
12:00
MR6
The LATAM PAG materials and methods
12:00
MR6
Key findings and results
12:00
MR6
Listening to the patient’s voice
12:00
MR6
Question & Answer
12:00
MR6
Closing
12:00
MR7
Where Do We Stand in the Non-Pharmacological Treatment of Osteoporosis?
Chairperson: Pinar Borman
Chairperson: Pinar Borman
12:00
MR7
Introduction to Non-Pharmacological Treatments in Osteoporosis
12:00
MR7
Exercise in Osteoporosis
12:00
MR7
Physical Therapy Modalities in Osteoporosis and its complications
12:00
MR7
Microbiota and Diet in Osteoporosis
12:00
MR8
The effect of hormonal treatment and cancer on bone health
Chairperson: Giuseppe Guglielmi
Chairperson: Giuseppe Guglielmi
12:00
MR8
Diagnostics methods for studying the bone damage in cancer patients
12:00
MR8
How can short-term monitoring be helpful to assess bone fragility in breast cancer patients?
12:00
MR8
Management of bone fragility in prostate cancer patients
12:00
MR10
Sleep apnea and Sarcopenia: a dream combo
Chairperson: Bruno Muzzi Camargos
Chairperson: Bruno Muzzi Camargos
12:00
MR10
Sleep disorders and sarcopenia - Assessment by Polysomnography
12:00
MR10
Sarcopenia and Osteoporosis - Assessment by Dual X-Ray Absorptiometry (DXA)
12:00
MR10
Questions and Answers